The price of VBI Vaccines Inc. (NASDAQ:VBIV) shares last traded on Wall Street fell -51.24% to $1.18.
Based on available information, 1 analysts follow VBI Vaccines Inc. (NASDAQ:VBIV). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $6.00, we find $6.00. Given the previous closing price of $2.42, this indicates a potential upside of 147.93 percent. VBIV stock price is now -56.84% away from the 50-day moving average and -90.28% away from the 200-day moving average. The market capitalization of the company currently stands at $9.72M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
Brokers who have rated the stock have averaged $6.00 as their price target over the next twelve months.
With the price target reduced from $5 to $2, Raymond James Downgraded its rating from Strong Buy to Outperform for VBI Vaccines Inc. (NASDAQ: VBIV).
In other news, PERCEPTIVE ADVISORS LLC, 10% Owner sold 4,251,563 shares of the company’s stock on Apr 06. The stock was sold for $467,672 at an average price of $0.11. Upon completion of the transaction, the 10% Owner now directly owns 41,440,729 shares in the company, valued at $48.9 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 05, 10% Owner PERCEPTIVE ADVISORS LLC sold 1,832,563 shares of the business’s stock. A total of $238,233 was realized by selling the stock at an average price of $0.13. This leaves the insider owning 45,691,816 shares of the company worth $53.92 million. A total of 0.52% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in VBIV stock. A new stake in VBI Vaccines Inc. shares was purchased by VICTORY CAPITAL MANAGEMENT INC during the first quarter worth $1,000. In total, there are 138 active investors with 44.40% ownership of the company’s stock.
A candlestick chart of VBI Vaccines Inc. (NASDAQ: VBIV) showed a price of $1.4200 on Thursday morning. During the past 12 months, VBI Vaccines Inc. has had a low of $1.76 and a high of $40.50. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 1.80, and a quick ratio of 1.50. The fifty day moving average price for VBIV is $2.7000 and a two-hundred day moving average price translates $12.0289 for the stock.
The latest earnings results from VBI Vaccines Inc. (NASDAQ: VBIV) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$3.22, missing analysts’ expectations of -$1.25 by -1.97. This compares to -$2.47 EPS in the same period last year. The company reported revenue of $0.48 million for the quarter, compared to $0.13 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 284.92 percent. For the current quarter, analysts expect VBIV to generate $930k in revenue.
VBI Vaccines Inc.(VBIV) Company Profile
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; GlaxoSmithKline Biologicals S.A.; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. It also has a collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.
